35,251 Shares in Orthofix Medical Inc. $OFIX Acquired by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd acquired 35,251 shares of Orthofix Medical Inc., valued at approximately $575,000, increasing its stake in the company to about 0.09% as of the latest SEC filing.
• Several research firms have recently upgraded their ratings for Orthofix Medical, with Barrington Research issuing a "strong-buy" rating and setting a price target of $16.00, while analysts have a consensus rating of "Buy" and an average target price of $21.50.
• Orthofix Medical reported a loss of ($0.36) EPS for the recent quarter, significantly missing analysts' estimates, while revenue exceeded expectations at $203.12 million.

Dynamic Technology Lab Private Ltd purchased a new position in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 35,251 shares of the medical device company's stock, valued at approximately $575,000. Dynamic Technology Lab Private Ltd owned about 0.09% of Orthofix Medical as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in OFIX. Lazard Asset Management LLC acquired a new stake in Orthofix Medical during the 4th quarter worth approximately $45,000. US Bancorp DE lifted its holdings in shares of Orthofix Medical by 684.6% in the 1st quarter. US Bancorp DE now owns 5,673 shares of the medical device company's stock valued at $93,000 after buying an additional 4,950 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Orthofix Medical in the 1st quarter valued at approximately $164,000. State of Wyoming increased its stake in Orthofix Medical by 206.8% in the 4th quarter. State of Wyoming now owns 9,432 shares of the medical device company's stock valued at $165,000 after purchasing an additional 6,358 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Orthofix Medical by 42.5% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,053 shares of the medical device company's stock valued at $229,000 after purchasing an additional 4,192 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms recently weighed in on OFIX. JMP Securities reaffirmed a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Barrington Research raised Orthofix Medical to a "strong-buy" rating and set a $16.00 price target for the company in a research report on Monday, June 23rd. Finally, Wall Street Zen raised Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $21.50.

Orthofix Medical Stock Down 2.5%

Shares of NASDAQ OFIX opened at $14.25 on Thursday. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.73. The firm's 50 day moving average price is $12.75 and its 200 day moving average price is $13.30. The firm has a market cap of $562.73 million, a P/E ratio of -4.50 and a beta of 0.86. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.40). The business had revenue of $203.12 million during the quarter, compared to analysts' expectations of $196.89 million. Orthofix Medical had a negative net margin of 15.29% and a negative return on equity of 25.43%. Orthofix Medical has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

Insider Activity at Orthofix Medical

In other news, insider Aviva Mcpherron sold 3,728 shares of Orthofix Medical stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total value of $39,181.28. Following the completion of the sale, the insider owned 46,322 shares of the company's stock, valued at $486,844.22. The trade was a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by corporate insiders.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.